|View printer-friendly version|
|Quidel Launches flutest.com; Interactive Web Site Delivers Practical Flu Solutions For Consumers|
SAN DIEGO--(BUSINESS WIRE)--Oct. 21, 2004--Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care diagnostic tests, today announced the launch of http://flutest.com -- a Web site dedicated to the latest information about influenza, including vaccine-related issues, rapid diagnostic tests and treatment options.
The recent news coverage surrounding the influenza vaccine shortage has left many consumers struggling to find accurate and reliable information about influenza. "We felt it was important to highlight the very critical role rapid flu testing may have this flu season. We take very seriously our responsibility as the innovator and market leader in flu testing to provide timely educational outreach to the public about the critical issues surrounding the flu," said Caren L. Mason, president and CEO of Quidel. Flutest.com offers relevant flu information, including nationwide surveillance information from the Centers for Disease Control and Prevention (CDC) and detailed information about Quidel's QuickVue(R) Influenza test, which can diagnose influenza in 10 minutes or less. The site features many consumer engagement tools, including:
Influenza, commonly referred to as the flu, is a serious disease and can lead to complications such as pneumonia and heart failure, and can worsen chronic diseases. If left undetected, influenza can lead to prolonged illness and may result in death. According to the CDC, influenza is responsible for approximately 36,000 deaths and more than 200,000 hospitalizations annually. Rates of infection are highest among young children, persons aged 65+ years, and anyone with chronic medical conditions.
Quidel Corporation is a global company dedicated to helping women and their families live healthy lives through the discovery, development, manufacture and marketing of rapid point-of-care (POC) diagnostic tests. These tests detect medical conditions and illnesses associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides POC diagnostic tests for infectious diseases, including influenza A & B, Strep A, H. pylori, Chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's diagnostic tests provide information that results in rapid treatment, improved health outcomes, lowered costs and increased patient satisfaction. Quidel's products are sold for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label products. For more information visit www.quidel.com
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risk and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration ("FDA"), intellectual property, product liability, environmental or other litigation, and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" in reports and registration statements that we file with the SEC from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.
CONTACT: Quidel Corporation